Clinical Relevance of Immune Monitoring in Solid Organ Transplantation

REFERENCES

• Murray J. E. Surgeon scientist. World J Surg 2000; 24: 757–758
   Google Scholar
• CTS Collaborative Transplant Study, Accessed 5 May, 2009 at: http://ctstransplant.org
   Google Scholar
• Banasik M., Klinger M. Chronic allograft nephropathy—immunologic and nonimmunologic factors. Ann Transplant 2006; 11: 7–10
   PubMedGoogle Scholar
• CTS Collaborative Transplant Study, unpublished data
   Google Scholar
• Bremer S., Mandla R., Vethe N. T., Rasmussen I., Rootwelt H., Line P. D., Midtvedt K., Bergan S. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008; 85: 55–61
   PubMed Web of Science ®Google Scholar
• Koch A., Daniel V., Dengler T. J., Schnabel P. A., Hagl S., Sack F. U. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant 2005; 24: 708–713
   Google Scholar
• Wavamunno M. D., Chapman J. R. Individualization of immunosuppression: Concepts and rationale. Curr Opin Organ Transplant 2008; 13: 604–608
   PubMed Web of Science ®Google Scholar
• Quteineh L., Verstuyft C., Furlan V., Durrbach A., Letierce A., Ferlicot S., Taburet A. M., Charpentier B., Becquemont L. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546–552
   PubMed Web of Science ®Google Scholar
• Ashton-Chess J., Giral M., Brouard S., Soulillou J. P. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007; 84: 1215–1219
   PubMed Web of Science ®Google Scholar
• Mazariegos G. V., Sindhi R., Thomson A. W., Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007; 17: 114–119
   PubMed Web of Science ®Google Scholar
• Beaudreuil S., Samuel D., Rouas-Freiss N., Durrbach A. New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?. Transpl Immunol 2007; 17: 98–107
   Google Scholar
• Wieërs G., Gras J., Bourdeaux C., Truong D. Q., Latinne D., Reding R. Monitoring tolerance after human liver transplantation. Transpl Immunol 2007; 17: 83–93
   PubMed Web of Science ®Google Scholar
• Newell K. A., Larsen C. P. Tolerance assays: Measuring the unknown. Transplantation 2006; 81: 1503–1509
   Google Scholar
• Lerut J., Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6: 1774–1780
   PubMed Web of Science ®Google Scholar
• Wilhelm M. J., Pratschke J., Beato F., Taal M., Kusaka M., Hancock W. W., Tilney N. L. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000; 102: 2426–2433
   Google Scholar
• Mikhalski D., Wissing K. M., Ghisdal L., Broeders N., Touly M., Hoang A. D., Loi P., Mboti F., Donckier V., Vereerstraeten P., Abramowicz D. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008; 85(7 Suppl)S3–9
   Google Scholar
• Choy B. Y., Chan T. M., Lai K. N. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6: 2535–2542
   Web of Science ®Google Scholar
• Hendrikx T. K., van Gurp E. A., Mol W. M., Schoordijk W., Sewgobind V. D., Ijzermans J. N., Weimar W., Baan C. C. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant Feb 4, 2009, [Epub ahead of print]
   Google Scholar
• Alvarez C. M., Opelz G., Giraldo M. C., Pelzl S., Renner F., Weimer R., Schmidt J., Arbeláez M., García L. F., Süsal C. Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant 2005; 5: 746–756
   PubMed Web of Science ®Google Scholar
• Bettens F., Tiercy J. M., Campanile N., Giostra E., Majno P., Rubbia L., Roosnek E., Mentha G., Villard J. Microchimerism after liver transplantation: absence of rejection without abrogation of anti-donor cytotoxic T-lymphocyte-mediated alloreactivity. Liver Transpl 2005; 11: 290–297
   PubMed Web of Science ®Google Scholar
• Mazariegos G. V., Zahorchak A. F., Reyes J., Ostrowski L., Flynn B., Zeevi A., Thomson A. W. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3: 689–696
   PubMed Web of Science ®Google Scholar
• Cortesini R., Suciu-Foca N. The concept of “partial” clinical tolerance. Transpl Immunol 2004; 13: 101–104
   Google Scholar
• Burlingham W. J., Pan M. H., Mason B., Ceman S., Sollinger H. W. Induction of antiidiotypic antibodies to donor HLA-A2 following blood transfusions in a highly sensitized HLA-A2+ recipient. Transplantation 1988; 45: 1066–1071
   Google Scholar
• Pratschke J., Tullius S. G., Neuhaus P. Brain death associated ischemia/reperfusion injury. Ann Transplant 2004; 9: 78–80
   Google Scholar
• Millán O., Brunet M., Campistol J. M., Faura A., Rojo I., Vidal E., Jiménez O., Vives J., Oppenheimer F., Martorell J. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003; 49: 1891–1899
   Google Scholar
• Brennan D. C., Flavin K., Lowell J. A., Howard T. K., Shenoy S., Burgess S., Dolan S., Kano J. M., Mahon M., Schnitzler M. A., Woodward R., Irish W., Singer G. G. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011–1018
   PubMed Web of Science ®Google Scholar
• Suzuki S., Toyabe S., Moroda T., Tada T., Tsukahara A., Iiai T., Minagawa M., Maruyama S., Hatakeyama K., Endoh K., Abo T. Circadian rhythm of leucocytes and lymphocytes subsets and its possible correlation with the function of the autonomic nervous system. Clin Exp Immunol 1997; 110: 500508
   Google Scholar
• Gerrits J. H., Athanassopoulos P., Vaessen L. M., Klepper M., Weimar W., van Besouw N. M. Peripheral blood manipulation significantly affects the result of dendritic cell monitoring. Transpl Immunol 2007; 17: 169–177
   Google Scholar
• Sommerer C., Giese T., Meuer S., Zeier M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit?. Nephrol Dial Transplant 2009; 24: 21–27
   Google Scholar
• Mahalati K., Belitsky P., Sketris I., West K., Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55–62
   PubMed Web of Science ®Google Scholar
• Morris R. G., Russ G. R., Cervelli M. J., Juneja R., McDonald S. P., Mathew T. H. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479–486
   Google Scholar
• Nemati E., Einollahi B., Taheri S., Moghani-Lankarani M., Kalantar E., Simforoosh N., Nafar M., Saadat A. R. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss?. Transplant Proc 2007; 39: 1223–1224
   Google Scholar
• Einecke G., Schütz M., Mai I., Fritsche L., Giessing M., Glander P., Neumayer H. H., Budde K. Limitations of C2 monitoring in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 1463–1470
   PubMed Web of Science ®Google Scholar
• Giese T., Zeier M., Schemmer P., Uhl W., Schoels M., Dengler T., Buechler M., Meuer S. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339–344
   PubMed Web of Science ®Google Scholar
• Sommerer C., Giese T., Schmidt J., Meuer S., Zeier M. Cyclosporine A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008; 85: 15–21
   Google Scholar
• Sommerer C., Konstandin M., Dengler T., Schmidt J., Meuer S., Zeier M., Giese T. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280–1285
   PubMed Web of Science ®Google Scholar
• Konstandin M. H., Sommerer C., Doesch A., Zeier M., Meuer S. C., Katus H. A., Dengler T. J., Giese T. Pharmacodynamic cyclosporine A-monitoring: Relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007; 20: 1036–1043
   Google Scholar
• Sommerer C., Hartschuh W., Enk A., Meuer S., Zeier M., Giese T. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22: 549–554
   Google Scholar
• Gras J., Wieërs G., Vaerman J. L., Truong D. Q., Sokal E., Otte J. B., Délépaut B., Cornet A., de Ville de Goyet J., Latinne D., Reding R. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 2007; 13: 426–433
   PubMed Web of Science ®Google Scholar
• Kim C. D., Ryu H. M., Choi J. Y., Choi H. J., Choi H. J., Cho J. H., Park S. H., Won D. I., Kim Y. L. Association of G-137C IL-18 promoter polymorphism with acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1610–1614
   PubMed Web of Science ®Google Scholar
• Girnita D. M., Brooks M. M., Webber S. A., Burckart G. J., Ferrell R., Zdanowicz G., DeCroo S., Smith L., Chinnock R., Canter C., Addonizio L., Bernstein D., Kirklin J. K., Ranganathan S., Naftel D., Girnita A. L., Zeevi A. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation 2008; 85: 1632–1639
   Google Scholar
• Singh R., Kesarwani P., Ahirwar D. K., Kapoor R., Mittal R. D. Interleukin 8 -251T > A and Interferon gamma +874A > T polymorphism: Potential predictors of allograft outcome in renal transplant recipients from north India. Transpl Immunol Feb 2, 2009, [Epub ahead of print]
   Google Scholar
• Grinyó J., Vanrenterghem Y., Nashan B., Vincenti F., Ekberg H., Lindpaintner K., Rashford M., Nasmyth-Miller C., Voulgari A., Spleiss O., Truman M., Essioux L. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21: 879–891
   PubMed Web of Science ®Google Scholar
• Mytilineos J., Laux G., Opelz G. Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 1684–1690
   Google Scholar
• Bayliss J., Maguire J. A., Bailey M., Leet A., Kaye D., Richardson M., Bergin P. J., Dowling J., Thomson N. M., Stein A. N. Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: A longitudinal study. Transpl Immunol 2008; 18: 264–274
   PubMedGoogle Scholar
• Brouard S., Mansfield E., Braud C., Li L., Giral M., Hsieh S. C., Baeten D., Zhang M., Ashton-Chess J., Braudeau C., Hsieh F., Dupont A., Pallier A., Moreau A., Louis S., Ruiz C., Salvatierra O., Soulillou J. P., Sarwal M. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007; 104: 15448–15453
   PubMed Web of Science ®Google Scholar
• Martínez-Llordella M., Lozano J. J., Puig-Pey I., Orlando G., Tisone G., Lerut J., Benítez C., Pons J. A., Parrilla P., Ramírez P., Bruguera M., Rimola A., Sánchez-Fueyo A. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845–2857
   PubMed Web of Science ®Google Scholar
• Augustine J. J., Poggio E. D., Heeger P. S., Hricik D. E. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008; 86: 529–534
   PubMed Web of Science ®Google Scholar
• van den Boogaardt D. E., van Miert P. P., de Vaal Y. J., de Fijter J. W., Claas F. H., Roelen D. L. The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006; 82: 844–848
   Google Scholar
• Pelzl S., Opelz G., Wiesel M., Schnülle P., Schönemann C., Döhler B., Süsal C. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3–6
   Google Scholar
• Süsal C., Pelzl S., Döhler B., Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650–1656
   PubMedGoogle Scholar
• Pelzl S., Opelz G., Daniel V., Wiesel M., Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75: 421–423
   PubMed Web of Science ®Google Scholar
• Weimer R., Süsal C., Yildiz S., Staak A., Pelzl S., Renner F., Dietrich H., Daniel V., Kamali-Ernst S., Ernst W., Padberg W., Opelz G. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: Impact of different immunosuppressive regimens. Am J Transplant 2006; 6: 1865–1874
   PubMed Web of Science ®Google Scholar
• Israeli M., Klein T., Sredni B., Avitzur Y., Mor E., Bar-Nathen N., Steinberg R., Dinari G., Shapiro R. ImmuKnow: A new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 2008; 14: 893–898
   Google Scholar
• Kowalski R. J., Post D. R., Mannon R. B., Sebastian A., Wright H. I., Sigle G., Burdick J., Elmagd K. A., Zeevi A., Lopez-Cepero M., Daller J. A., Gritsch H. A., Reed E. F., Jonsson J., Hawkins D., Britz J. A. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 82: 663–668
   PubMed Web of Science ®Google Scholar
• Cabrera R., Ararat M., Soldevila-Pico C., Dixon L., Pan J. J., Firpi R., Machicao V., Levy C., Nelson D., Morelli G. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl 2009; 15: 216–222
   PubMed Web of Science ®Google Scholar
• Bhorade S. M., Janata K., Vigneswaran W. T., Alex C. G., Garrity E. R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008; 27: 990–994
   Google Scholar
• Gautam A., Fischer S. A., Yango A. F., Gohh R. Y., Morrissey P. E., Monaco A. P. Cell mediated immunity (CMI) and post transplant viral infections—role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 2006; 6: 2023–2026
   Google Scholar
• Tokita D., Mazariegos G. V., Zahorchak A. F., Chien N., Abe M., Raimondi G., Thomson A. W. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008; 85: 369–377
   PubMed Web of Science ®Google Scholar
• Daniel V., Naujokat C., Sadeghi M., Wiesel M., Hergesell O., Opelz G. Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation 2005; 79: 1498–1506
   Google Scholar
• Hackstein H., Renner F. C., Bohnert A., Nockher A., Frommer T., Bein G., Weimer R. Dendritic cell deficiency in the blood of kidney transplant patients on long-term immunosuppression: Results of a prospective matched-cohort study. Am J Transplant 2005; 5: 2945–2953
   PubMed Web of Science ®Google Scholar
• Brandacher G., Cakar F., Winkler C., Schneeberger S., Obrist P., Bösmüller C., Werner-Felmayer G., Werner E. R., Bonatti H., Margreiter R., Fuchs D. Noninvasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007; 71: 60–67
   PubMed Web of Science ®Google Scholar
• Dubiński B., Boratyńska M., Kopeć W., Szyber P., Patrzałek D., Klinger M. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)—sensitive rejection markers in renal graft recipients. Transpl Immunol 2008; 18: 203–207
   PubMed Web of Science ®Google Scholar
• Blanco-Garcia R. M., López-Alvarez M. R., Pascual-Figal D. A., Polo-Garcia L., Guerra N., Campillo J. A., Muro M., Garcia-Alonso A. M., Marin-Moreno I., Valdes M., Alvarez-López M. R., Minguela A. Expression of HLA molecules on peripheral blood lymphocytes: A useful monitoring parameter in cardiac transplantation. Transplant Proc 2007; 39: 2362–2364
   Google Scholar
• Galante N. Z., Câmara N. O., Kallas E. G., Salomão R., Pacheco-Silva A., Medina-Pestana J. O. Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients. Transpl Immunol 2006; 16: 73–80
   Google Scholar
• Saas P., Courivaud C., Bamoulid J., Garnache-Ottou F., Seilles E., Ducloux D. Immune monitoring of kidney transplant recipients: Can markers predictive of over-immunosuppression be identified?. Ann Pharm Fr 2008; 66: 115–121
   Google Scholar
• Huurman V. A., Hilbrands R., Pinkse G. G., Gillard P., Duinkerken G., van de Linde P., van der Meer-Prins P. M., Versteeg-van der Voort Maarschalk M. F., Verbeeck K., Alizadeh B. Z., Mathieu C., Gorus F. K., Roelen D. L., Claas F. H., Keymeulen B., Pipeleers D. G., Roep B. O. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008; 3: e2435
   PubMed Web of Science ®Google Scholar
• Bestard O., Cruzado J. M., Mestre M., Caldés A., Bas J., Carrera M., Torras J., Rama I., Moreso F., Serón D., Grinyó J. M. Achieving donor-specific hyporesponsiveness is associated with FOXP3+ regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901–4909
   PubMed Web of Science ®Google Scholar
• Demirkiran A., Baan C. C., Kok A., Metselaar H. J., Tilanus H. W., van der Laan L. J. Intrahepatic detection of FOXP3 gene expression after liver transplantation using minimally invasive aspiration biopsy. Transplantation 2007; 83: 819–823
   Google Scholar
• Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J. B., Hartono C., Li B., Sharma V. K., Seshan S. V., Kapur S., Hancock W. W., Schwartz J. E., Suthanthiran M. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342–2351
   PubMed Web of Science ®Google Scholar
• Kreijveld E., Koenen H. J., van Cranenbroek B., van Rijssen E., Joosten I., Hilbrands L. B. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS ONE 2008; 3: e2711
   PubMed Web of Science ®Google Scholar
• Daniel V., Naujokat C., Sadeghi M., Weimer R., Renner F., Yildiz S., Opelz G. Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int 2008; 21: 646–660
   PubMed Web of Science ®Google Scholar
• Pretagostini R., Cinti P., Lai Q., Poli L., Berloco P. B. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transpl Immunol 2008; 20: 3–5
   PubMed Web of Science ®Google Scholar
• Zou Y., Stastny P., Süsal C., Döhler B., Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293–1300
   PubMed Web of Science ®Google Scholar
• Panigrahi A., Gupta N., Siddiqui J. A., Margoob A., Bhowmik D., Guleria S., Mehra N. K. Monitoring of anti-HLA and anti-Major histocompatibility complex class I related chain A antibodies in living related renal donor transplantation. Transplant Proc 2007; 39: 759–760
   PubMed Web of Science ®Google Scholar
• Kobayashi T., Kohara S., Miwa Y., Nagasaka T., Goto N., Katayama A., Uchida K., Nakao A. Clinical value of HLA antibody monitoring after renal transplantation. Clin Transpl 2006; 385–388
   Google Scholar
• Piazza A., Poggi E., Ozzella G., Borrelli L., Scornajenghi A., Iaria G., Tisone G., Adorno D. Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: Results of sixteen-year monitoring by flow cytometry. Clin Transpl 2006; 323–336
   PubMedGoogle Scholar
• Mizutani K., Terasaki P., Hamdani E., Esquenazi V., Rosen A., Miller J., Ozawa M. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027–1031
   Google Scholar
• Pollinger H. S., Stegall M. D., Gloor J. M., Moore S. B., Degoey S. R., Ploeger N. A., Park W. D., Pollinger H. S., Stegall M. D., Gloor J. M., Moore S. B., Degoey S. R., Ploeger N. A., Park W. D. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857–863
   PubMedGoogle Scholar
• Kasiske B. L., Chakkera H. A., Louis T. A., Ma J. Z. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910–1917
   PubMed Web of Science ®Google Scholar
• Smak Gregoor P. J., de Sévaux R. G., Ligtenberg G., Hoitsma A. J., Hené R. J., Weimar W., Hilbrands L. B., van Gelder T. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365–1373
   PubMedGoogle Scholar
• Abramowicz D., Del Carmen Rial M., Vitko S., del Castillo D., Manas D., Lao M., Gafner N., Wijngaard P., Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234–2240
   PubMed Web of Science ®Google Scholar
• Calne R. Y. Immunological tolerance—the liver effect. Immunol Rev 2000; 174: 280–282
   Google Scholar